Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice | Zendy

Bruno Masquelier | Zendy; I. Cohen Codar | Zendy; Cathia Soulié | Zendy; Constance Delaugerre | Zendy; L. Morand-Joubert | Zendy; C. Charpentier | Zendy; Virginie Ferré | Zendy; JeanChristophe Plantier | Zendy; Brigitte Montès | Zendy; S. Carret | Zendy; V. Perrot | Zendy; G. Peytavin | Zendy; Dominique Costagliola | Zendy; Vincent Cálvez | Zendy; AnneGeneviève Marcelin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice

Author(s) -

Bruno Masquelier,

I. Cohen Codar,

Cathia Soulié,

Constance Delaugerre,

L. Morand-Joubert,

C. Charpentier,

Virginie Ferré,

JeanChristophe Plantier,

Brigitte Montès,

S. Carret,

V. Perrot,

G. Peytavin,

Dominique Costagliola,

Vincent Cálvez,

AnneGeneviève Marcelin

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks226

Subject(s) - lopinavir , ritonavir , lopinavir/ritonavir , medicine , protease inhibitor (pharmacology) , observational study , virology , protease , human immunodeficiency virus (hiv) , pharmacology , antiretroviral therapy , viral load , biology , enzyme , biochemistry

This observational study was requested by French health authorities to determine the impact of lopinavir/ritonavir (Kaletra(®)) on antiretroviral resistance in clinical practice. Virological failures of lopinavir/ritonavir and their effects on the resistance to protease inhibitors and reverse transcriptase inhibitors were evaluated in protease inhibitor-experienced patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research